Listed by the USPTO as BRISTOL, LYNN ANNE
Tech Center 1600 • Art Units: 1600 1617 1643 1645 1646
This examiner grants 63% of resolved cases
BRISTOL, LYNN ANNE examines in Tech Center 1600 and Art Unit 1600. Her profile records 1160 resolved cases, an allowance rate of 63.4%, and a median of 1230 days to allowance. Interviews show a 39.8% lift, the strongest directional feature in the available metrics, making interview preparation an important practical consideration for prosecution before this examiner.
The listed companies are Hoffmann-La Roche Inc., Amgen Inc., and Sanofi S.A. The leading firms are STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., Hoffmann & Baron LLP, and MEDLER FERRO WOODHOUSE & MILLS PLLC. These organizations identify representative life sciences activity and counsel relationships, while the allowance and timing figures indicate the need to plan for extended prosecution.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17910327 | AFFINITY MATURED AND HUMANIZED BINDING DOMAINS TARGETING ROR2 | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED |
| 18600323 | ANTI-TIM3 ANTIBODIES AND METHODS OF USE | Non-Final OA | Hoffmann-La Roche Inc. |
| 18051307 | PREDICTING RESPONSE TO PD-1 AXIS INHIBITORS | Non-Final OA | Hoffmann-La Roche Inc. |
| 17937440 | BISPECIFIC ANTIBODIES COMPRISING A MODIFIED C-TERMINAL CROSSFAB FRAGMENT | Non-Final OA | Hoffmann-La Roche Inc. |
| 17381145 | IMMUNOGLOBULIN A ANTIBODIES AND METHODS OF PRODUCTION AND USE | Non-Final OA | GENENTECH, INC. |
| 17257391 | ANTIBODY TUMOR-TARGETING ASSEMBLY COMPLEXES | Non-Final OA | THE GENERAL HOSPITAL CORPORATION |
| 18538279 | ANTIBODY CONSTRUCTS FOR MSLN AND CD3 | Non-Final OA | AMGEN INC. |
| 18042267 | ANTIGEN BINDING PROTEINS WITH NON-CANONICAL DISULFIDE IN FAB REGION | Final Rejection | AMGEN INC. |
| 16869793 | DOSING REGIMEN FOR ANTI-BCMA AGENTS | Non-Final OA | AMGEN INC. |
| 18268840 | EFFECTORLESS FC MOLECULES | Final Rejection | SANOFI |
| 15734301 | UNIVERSAL OR NORMALIZED ANTIBODY FRAMEWORKS FOR IMPROVED FUNCTIONALITY AND MANUFACTURABILITY | Non-Final OA | Ventana Medical Systems, Inc. |
| 16435257 | TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18284009 | TRUNCATED TACI POLYPEPTIDE AND FUSION PROTEIN AND USE THEREOF | Non-Final OA | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. |
| 17230240 | MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATABLE ANTIBODIES AND METHODS OF USING THE SAME | Non-Final OA | CytomX Therapeutics, Inc. |
| 18025203 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | Non-Final OA | GENMAB A/S |
| 17759282 | HETERODIMERIC PROTEINS WITH FC MUTATIONS | Non-Final OA | Adagene AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy63.4% of resolved applications examined by Lynn Anne Bristol were allowed (1,160 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +39.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Lynn Anne Bristol took 1,230 days on average from filing to allowance.
Lynn Anne Bristol examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
